Quanterix (QTRX) Corporation announced plans to debut its Content Innovation Engine at the American Association for Cancer Research, AACR, Annual Meeting 2026. Built on the integration of Akoya Biosciences’ spatial biology platform and Quanterix’s decades of ultra-sensitive, quantitative immunoassay development from the SIMOA technology, the Content Innovation Engine is organized around the hallmarks of cancer framework, giving researchers a systematic, biology-first approach to revealing more from every tissue section.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Quanterix Balances Growth Optics With Underlying Weakness
- Quanterix: Encouraging Q4 Beat but Fragile Recovery and Limited Visibility Keep Rating at Hold
- Quanterix Faces Significant Supply Chain Risk From Single-Source Instrument Manufacturers
- Quanterix reports Q4 EPS (49c) vs. (30c) last year
- Quanterix sees FY26 revenue $169M-$174M, consensus $168.8M